U.S. markets open in 5 hours 47 minutes
  • S&P Futures

    3,857.00
    +37.75 (+0.99%)
     
  • Dow Futures

    31,988.00
    +212.00 (+0.67%)
     
  • Nasdaq Futures

    12,517.25
    +220.00 (+1.79%)
     
  • Russell 2000 Futures

    2,227.60
    +26.80 (+1.22%)
     
  • Crude Oil

    65.02
    -0.03 (-0.05%)
     
  • Gold

    1,695.00
    +17.00 (+1.01%)
     
  • Silver

    25.63
    +0.36 (+1.43%)
     
  • EUR/USD

    1.1889
    +0.0037 (+0.31%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.94
    +0.28 (+1.14%)
     
  • GBP/USD

    1.3886
    +0.0064 (+0.46%)
     
  • USD/JPY

    108.7200
    -0.1810 (-0.17%)
     
  • BTC-USD

    53,998.72
    +4,128.40 (+8.28%)
     
  • CMC Crypto 200

    1,087.77
    +63.56 (+6.21%)
     
  • FTSE 100

    6,720.33
    +1.20 (+0.02%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Preview: Neurocrine Biosciences's Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Neurocrine Biosciences (NASDAQ: NBIX) will be releasing its next round of earnings this Monday, November 09. For all of the relevant information, here is your guide for Monday's Q3 earnings announcement.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Neurocrine Biosciences's per-share loss will be near $0.06 on sales of $283.04 million, according to Wall Street analysts. In the same quarter last year, Neurocrine Biosciences reported earnings per share of $0.56 on revenue of $222.09 million.

Why Analyst Estimates And Earnings Surprises Are Important

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

View more earnings on NBIX

If the company were to match the consensus estimate, earnings would be down 110.71%. Revenue would be up 27.44% on a year-over-year basis. Here is how the company's reported EPS has compared to analyst estimates in the past:

EPS Estimate

0.73

0.54

0.75

0.64

EPS Actual

1.42

0.82

1.05

0.56

Revenue Estimate

260.34 M

223.87 M

230.94 M

211.63 M

Revenue Actual

302.40 M

237.10 M

244.10 M

222.09 M

Stock Performance

Shares of Neurocrine Biosciences were trading at $100.32 as of November 05. Over the last 52-week period, shares are down 11.32%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Neurocrine Biosciences is scheduled to hold the call at 16:30:00 ET and can be accessed here.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.